Trials / Enrolling By Invitation
Enrolling By InvitationNCT07280221
WEgovy Real World Assessment of Weight Loss in Korea
WEgovy Real World Assessment of Weight Loss in Korea (WE-WALK): a Multi-centre, Prospective, Single-arm, Nonintervention Study to Investigate the Effectiveness and Safety of Once-weekly Semaglutide 2.4 mg for People Living With Obesity in Routine Clinical Practice in Korea
- Status
- Enrolling By Invitation
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice. The purpose of this study is to investigate the change in body weight and other clinical characteristics related to body weight in patients living with obesity. Participants will be treated with Wegovy (semaglutide) as prescribed by their doctor, in accordance with normal clinical practice. The study will last for about 52 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Semaglutide | Semaglutide injection will be self-administered once weekly subcutaneously. |
Timeline
- Start date
- 2025-11-10
- Primary completion
- 2027-10-31
- Completion
- 2027-10-31
- First posted
- 2025-12-12
- Last updated
- 2025-12-12
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT07280221. Inclusion in this directory is not an endorsement.